The University of São Paulo (USP) developed a vaccine for covid-19 spray, presented the proposal to the National Health Surveillance Agency (Anvisa) and is awaiting authorization to start studies in humans. The immunizing agent developed by the Instituto do Coração (InCor) of the Hospital das Clínicas (HC) of the Faculty of Medicine (FMUSP) of USP aims to be one more tool to combat the new coronavirus.
“We studied in detail the immune response of 220 convalescents who had had the disease, who recovered, and then we thought of a peptide, studying the virus well, that would contemplate a very strong antibody response that neutralizes the virus, but also this one. a good cellular response”, said, in an interview to Jornal da USP, Jorge Kalil Filho, professor of Clinical Immunology and Allergy at FMUSP, director of the Immunology Laboratory at InCor and coordinator of the vaccine development research.
::Vaccination advances, deaths fall, but the covid is not over: how to return to normal life in safety?::
Kalil explains that the nasal administration of the vaccine was due to the application being carried out in the same region where the virus enters the human body. Immunoglobulin A (IgA) is responsible for the defense against the coronavirus. The aim is to stimulate these cells of the immune system located in the nasal mucosa, in order to create a greater number of antibodies.
According to the professor, intramuscular vaccines produce a smaller amount of antibodies, and the spray version is a more effective way of creating a defense against the disease, such as preventing infection.
The immunizing agent presented in its initial tests a great immune response when applied. Currently, Anvisa has been asked for authorization to start the clinical trial in people. The tests aim to understand what is the most efficient way for the vaccine to work in volunteers. The study will test questions related to the number of doses, amount of immunizing agent and how it reacts in different organisms.
::Study detects “unvaccinated pandemic” in Brazil, as happened in the US and Israel::
Instituto Butantan also advances in the creation of its own vaccine
ButanVac, another vaccine candidate against covid being developed by the state of São Paulo, had its effectiveness proven against the alpha, beta and gamma variants during preclinical studies, according to results published recently in the scientific journal “Nature Communications”.
In this phase of the studies, the tests were carried out in guinea pigs and usually precede the application phase in humans. Despite this, the developers have already released a preview of phase 1 results, with volunteers, which indicate that ButanVac is safe and generates an immune response in patients.
According to the journal Nature, the vaccine being developed at the Butantan Institute uses the inactivated virus for intramuscular administration, through injection.
Edition: Vinícius Segalla